University of Pittsburgh Cancer Institute gets NCI preclinical research contract

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE UNIVERSITY OF PITTSBURGH CANCER INSTITUTE, partnered with UPMC CancerCancer, received a contract from NCI to perform preclinical research for the development of new cancer drugs. This commitment could bring up to $10 million in research projects to UPCI over the next five years.

Julie Eiseman, professor of pharmacology and chemical biology, and Jan Beumer, associate professor of pharmaceutical sciences and medicine, will serve as co-principal investigators on the research contract. They also hold a previous NCI preclinical contract, which will conclude next year. The researchers do not yet know specifically what potential drugs they’ll be investigating or in which indications.

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login